Chest
Volume 124, Issue 4, Supplement, January 2003, Page 182S
Cost-effectiveness of Linezolid for Treatment of Ventilator-Associated Pneumoni
Section snippets
Abstract
PURPOSE: Our goals were to determine the incremental cost-effectiveness of linezolid (LIN) compared to vancomycin (VAN) for VAP due to S. aureus and to investigate the cost-effectiveness of broader use of bronchoscopy (FOB) in the management of VAP.
METHODS: We modeled the cost and efficacy of LIN vs. VAN for treatment of VAP. The primary outcome was the incremental cost-effectiveness of LIN in terms of cost per added quality-adjusted life-year (QALY) gained. A second model investigated the
References (0)
Cited by (59)
Chlorhexidine-silver sulfadiazine-impregnated venous catheters are efficient even at subclavian sites without tracheostomy
2016, American Journal of Infection ControlEstimating duration of central venous catheter at time of insertion: Clinician judgment and clinical predictors
2015, Journal of Critical CareEfficiency of chlorhexidine-silver sulfadiazine-impregnated venous catheters at subclavian sites
2015, American Journal of Infection ControlCost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access
2014, American Journal of Infection ControlChlorhexidine-silver sulfadiazine-impregnated venous catheters save costs
2014, American Journal of Infection ControlCentral venous catheter-related biofilm infections: An up-to-date focus on meticillin-resistant Staphylococcus aureus
2013, Journal of Global Antimicrobial Resistance
Copyright © 2003 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.